Phase I clinical trials were initiated when anti-PD-1 and anti-PD-L1 monoclonal antibodies showed therapeutic effectiveness against a range of tumor types, including renal cell carcinoma, melanoma, and non-small-cell lung cancer (NSCLC) (93). This evidence concerns the gene PDCD1 and neoplasm.